Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat Internacional de Catalunya > Recerca > Articles > Ciències de la Salut > View document

To access the full text documents, please follow this link: http://hdl.handle.net/20.500.12328/1846

dc.contributor.author	Rubio-Rivas, Manuel
dc.contributor.author	Ronda, Mar
dc.contributor.author	Padullés, Ariadna
dc.contributor.author	Mitjavila, Francesca
dc.contributor.author	Riera-Mestre, Antoni
dc.contributor.author	García-Forero, Carlos
dc.contributor.author	Iriarte, Adriana
dc.contributor.author	Mora-Luján, José María
dc.contributor.author	Padullés, Núria
dc.contributor.author	Gonzalez, Monica
dc.contributor.author	Solanich, Xavier
dc.contributor.author	Gasa, Merce
dc.contributor.author	Suarez-Cuartin, Guillermo
dc.contributor.author	Sabater-Riera, Joan
dc.contributor.author	Perez-Fernandez, Xose L.
dc.contributor.author	Santacana, Eugenia
dc.contributor.author	Leiva, Elisabet
dc.contributor.author	Ariza-Sole, Albert
dc.contributor.author	Dallaglio, Paolo D.
dc.contributor.author	Quero, Maria
dc.contributor.author	Soriano, Antonio
dc.contributor.author	Pasqualetto, Alberto
dc.contributor.author	Koo, Maylin
dc.contributor.author	Esteve-Luque, Virginia
dc.contributor.author	Antolí, Arnau
dc.contributor.author	Moreno-Gónzalez, Rafael
dc.contributor.author	Yun, Sergi
dc.contributor.author	Cerdà, Pau
dc.contributor.author	Llaberia, Mariona
dc.contributor.author	Formiga, Francesc
dc.contributor.author	Fanlo-Maresma, Marta
dc.contributor.author	Montero, Abelardo
dc.contributor.author	Chivite, David
dc.contributor.author	Capdevila, Olga
dc.contributor.author	Bolao, Ferran
dc.contributor.author	Pintó, Xavier
dc.contributor.author	Llop, Josep
dc.contributor.author	Sabate, Antoni
dc.contributor.author	Guardiola, Jordi
dc.contributor.author	Cruzado, Josep M.
dc.contributor.author	Comin-Colet, Josep
dc.contributor.author	Santos, Salud
dc.contributor.author	Jodar, Ramon
dc.contributor.author	Corbella Virós, Xavier
dc.date	2020-12-17T17:06:09Z
dc.date	2020-12-17T17:06:09Z
dc.date	2020-12
dc.identifier	Rubio-Rivas, Manuel; Ronda, Mar; Padulles, Ariadna [et al.].
dc.identifier	Rubio-Rivas, Manuel; Ronda, Mar; Padulles, Ariadna [et al.]. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. International Journal of Infectious Diseases, 2020, 101, p. 290-297. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/33035673/>. Fecha de acceso: 12 ene. 2021. DOI: 10.1016/j.ijid.2020.09.1486
dc.identifier	1201-9712
dc.identifier	http://hdl.handle.net/20.500.12328/1846
dc.identifier	https://dx.doi.org/10.1016/j.ijid.2020.09.1486
dc.identifier.uri	http://hdl.handle.net/20.500.12328/1846
dc.description	Objectives: To assess the characteristics and risk factors for mortality in patients with severe coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in combination with corticosteroids (CS). Methods: From March 17 to April 7, 2020, a real-world observational retrospective analysis of consecutive hospitalized adult patients receiving TCZ to treat severe COVID-19 was conducted at our 750-bed university hospital. The main outcome was all-cause in-hospital mortality. Results: A total of 1,092 patients with COVID-19 were admitted during the study period. Of them, 186 (17%) were treated with TCZ, of which 129 (87.8%) in combination with CS. Of the total 186 patients, 155 (83.3 %) patients were receiving noninvasive ventilation when TCZ was initiated. Mean time from symptoms onset and hospital admission to TCZ use was 12 (±4.3) and 4.3 days (±3.4), respectively. Overall, 147 (79%) survived and 39 (21%) died. By multivariate analysis, mortality was associated with older age (HR = 1.09, p < 0.001), chronic heart failure (HR = 4.4, p = 0.003), and chronic liver disease (HR = 4.69, p = 0.004). The use of CS, in combination with TCZ, was identified as a protective factor against mortality (HR = 0.26, p < 0.001) in such severe COVID-19 patients receiving TCZ. No serious superinfections were observed after a 30-day follow-up. Conclusions: In patients with severe COVID-19 receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed a beneficial effect in preventing in-hospital mortality.
dc.format	8
dc.format	application/pdf
dc.language	eng
dc.publisher	International Journal of Infectious Diseases
dc.relation	Elsevier
dc.relation	101;
dc.rights	© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights	https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Esteroides
dc.subject	Corticosteroides
dc.subject	COVID-19 (Malaltia)
dc.subject	Mortalitat
dc.subject	Esteroides
dc.subject	Corticosteroides
dc.subject	COVID-19
dc.subject	Mortalidad
dc.subject	Steroids
dc.subject	Corticosteroids
dc.subject	COVID-19
dc.subject	Mortality
dc.subject	61
dc.subject	616.9
dc.title	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion

Show simple item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author